The biology, the full treatment protocol, and why the acne of midlife is categorically different from teenage skin

The Acne Nobody Expects at This Age

You cleared your skin in your late twenties. You stopped thinking about breakouts. Then, somewhere in your mid-to-late forties, they returned – and not as the occasional pre-period spot you might remember from your 30s. These are different: deeper, more painful, slower to heal, and in locations you never experienced before. Along the jawline. Under the chin. At the sides of the cheeks. Sometimes cystic – large, hard, painful nodules that take weeks to resolve and leave marks behind.

The timing is bewildering. You are approaching menopause – hormones are declining, not raging – and yet your skin is behaving in a way that feels more volatile, not less.

This is hormonal acne in perimenopause and menopause, and it is both more common and more treatable than most women are led to believe.

Menopausal acne affects 12–22% of women, causing significant emotional distress and quality of life impact, especially in those with darker skin due to scarring. Although perimenopausal and menopausal acne are becoming more common in dermatology clinics each year, it remains an underexplored area of research.

This article provides the complete guide: the biology, the clinical distinction from other acne types, the full step-by-step treatment protocol from the 2024 updated AAD guidelines, and the nutritional and lifestyle strategies that support it.

Part 1: Why Menopause Triggers Acne

The Hormonal Imbalance at the Root

The mechanism of hormonal acne during perimenopause is distinct from both teenage acne and the premenstrual spots of the reproductive years – though they share common downstream pathways. Understanding the distinction matters because it directly informs treatment.

During menopause, estrogen declines faster than male hormones like testosterone. This imbalance triggers the sebaceous glands to pump out more oil, making it easier for hair follicles to clog and for acne to develop.

In the reproductive years, estrogen maintains a relative balance with androgens (testosterone and dihydrotestosterone, or DHT). Estrogen has direct anti-androgenic effects at the skin level: it down-regulates the enzyme 5-alpha-reductase (which converts testosterone to the more potent DHT), reduces the sensitivity of sebaceous glands to androgen stimulation, and maintains the skin barrier integrity that prevents bacterial colonization.

As estrogen declines in perimenopause, these protective effects are withdrawn – not because androgen levels themselves rise dramatically, but because the relative balance shifts. Androgens that were previously “counterbalanced” by estrogen now have greater net influence on sebaceous gland activity. In most cases, adult acne is caused by hormonal imbalances in which the body produces too much androgen, or increased sensitivity to normal levels of androgen at the level of the skin.

The cascade that follows is well-documented: increased androgen stimulation of sebaceous glands → increased sebum production → sebum accumulation in follicles → altered sebum composition (more comedogenic) → follicular plugging → proliferation of Cutibacterium acnes (the primary acne-causing bacterium) → inflammatory response → the visible lesion.

Why Menopausal Acne Is Different from Teenage Acne

The three characteristics that clinically distinguish perimenopausal and menopausal acne from teenage acne are location, lesion type, and skin context:

Location: Teenage acne is distributed across the T-zone – forehead, nose, chin – where sebaceous gland density is highest. Menopausal hormonal acne is strongly localized to the lower face: the jawline, chin, lower cheeks, and perioral area. This distribution reflects the specific androgen-receptor density in these facial regions and is the single most reliable clinical indicator that the acne is hormonally driven.

Lesion type: Teenage acne is predominantly comedonal (blackheads, whiteheads) and superficially inflammatory. Menopausal acne tends to be deeper – inflammatory papules and pustules that sit within the dermis rather than close to the skin surface, and nodular/cystic lesions that are hard, painful, slow to come to a head, and prone to scarring and post-inflammatory hyperpigmentation (PIH). The depth of these lesions explains why superficial topical treatments that work for teenage acne are often inadequate for menopausal skin.

Skin context: Menopausal skin is simultaneously drier, thinner, and more barrier-compromised than teenage skin – driven by estrogen’s loss of its collagen-stimulating, ceramide-supporting, and sebum-balancing effects. This creates the paradoxical presentation that confuses many women and clinicians: acne on dry, sensitive, ageing skin. Treatment products designed for teenage oily skin – high-strength benzoyl peroxide, aggressive retinols, alcohol-based toners – cause significant barrier disruption in menopausal skin and worsen the underlying condition even as they target the acne.

The Skin Microbiome Dimension

An emerging and important dimension of menopausal acne concerns the skin microbiome. Estrogen deficiency alters the skin’s surface pH, reducing its acidity and creating conditions that favor the overgrowth of both Cutibacterium acnes (the acne bacterium) and inflammatory skin dysbiosis more broadly. The reduced ceramide content of menopausal skin weakens the barrier function that normally prevents bacterial translocation into follicles, and the reduced skin turnover rate of ageing skin means that dead cells linger longer in follicles – providing more substrate for bacterial colonization.

Cortisol as Amplifier

The elevated cortisol of perimenopause – driven by the neurobiological effects of hormonal change, sleep disruption, and midlife contextual stressors – directly worsens acne through its effects on sebaceous gland activity. Cortisol stimulates sebum production through its direct action on sebaceous gland receptors, and stress-driven cortisol spikes reliably precede acne flares by 48–72 hours. This is not psychosomatic – it is a documented neuroendocrine-dermatological pathway.

Part 2: The Clinical Assessment – What Needs Investigating

Most hormonal acne during perimenopause does not require extensive investigation – the clinical history and distribution are typically diagnostic. However, certain presentations warrant assessment:

Request blood tests for:

• Testosterone (free and total) and DHEA-S (dehydroepiandrosterone sulphate) – markedly elevated androgen levels may indicate an underlying condition (polycystic ovary syndrome, adrenal dysfunction, or rarely a hormone-secreting tumor) that requires specific management beyond topical acne treatment
• LH and FSH – to confirm perimenopause status if this is uncertain
• Thyroid function (TSH) – hypothyroidism can both cause and worsen acne
• Fasting glucose and HbA1c – insulin resistance (increasingly common in perimenopause) directly stimulates androgen production through its effects on IGF-1 signaling

Seek dermatological assessment when:

• Acne is significantly scarring or causing post-inflammatory hyperpigmentation
• Standard topical treatments have not produced improvement after 8–12 weeks
• Deep, cystic, or nodular lesions are present – these require systemic treatment and should not be managed with over-the-counter products alone
• There is concurrent hirsutism (increased facial hair), significant hair thinning, or menstrual irregularity suggesting androgen excess

Part 3: The 2024 Updated Treatment Protocol

The American Academy of Dermatology (AAD) published updated acne management guidelines in January 2024 – the most comprehensive clinical framework to date. Updated guidelines recommend hormonal therapies such as combined oral contraceptives or spironolactone to address hormonal causes of acne; topical clascoterone, which addresses hormonal causes of acne; topical salicylic acid to unclog pores and exfoliate the skin; topical azelaic acid to unclog pores, kill bacteria, and fade dark spots. For patients with severe acne or for patients who have failed standard treatment with oral or topical therapy, the guidelines recommend isotretinoin.

The following is the full evidence-based treatment protocol, structured as a step-up approach from gentlest to most intensive:

Step 1: Skincare Foundations – Non-Negotiable Before Anything Else

The most common treatment failure in perimenopausal acne is applying anti-acne products to a compromised, dehydrated, irritated skin barrier – and blaming treatment resistance when the real problem is barrier dysfunction. Every topical acne treatment works better on a healthy, intact skin barrier.

Gentle, pH-balanced cleanser – non-foaming or low-foam, fragrance-free, pH 4.5–5.5. Avoid bar soaps, high-strength salicylic acid washes, and products with alcohol as a primary ingredient. Clean twice daily; warm rather than hot water.

Hydration first – a ceramide-containing moisturizer is the foundation layer, applied before any active treatment. This is not optional in menopausal skin – it is the prerequisite for tolerating any topical acne ingredient.

Broad-spectrum SPF 30+ daily – UV exposure worsens PIH (the dark marks left by healed acne) and exacerbates the skin inflammation underlying acne. Non-comedogenic mineral sunscreens (zinc oxide, titanium dioxide) are preferred for acne-prone skin.

Step 2: Topical Actives – The Evidence-Based First Line

For menopausal acne specifically, the choice of topical actives must balance efficacy against barrier tolerance. Not all teenage acne staples are appropriate.

Azelaic acid (10–20%) – the most versatile and best-tolerated topical active for menopausal acne. It works through multiple mechanisms: antibacterial (directly inhibits C. acnes), comedolytic (loosens follicular plugs), anti-inflammatory, and melanin synthesis-inhibiting (fades PIH). Unlike benzoyl peroxide and high-strength retinoids, it is very well tolerated on dry, sensitive skin and can be used twice daily without a tolerance period. Available as 10% over the counter (in the EU, UK) and 15–20% prescription strength. This is the first topical choice for most women with perimenopausal acne.

Niacinamide (4–5%) – reduces sebum production through modulation of the sebocyte cell cycle, has proven anti-inflammatory properties, strengthens the skin barrier, and reduces PIH. Not a standalone acne treatment but a significant and highly tolerable adjunct. Can be used daily without restriction.

Salicylic acid (0.5–2%) – a beta-hydroxy acid that penetrates oil-filled pores to dissolve the sebum-dead cell plugs underlying comedonal acne. Most appropriate for comedonal rather than cystic lesions. At 0.5–1% (rather than the 2% commonly found in teenage acne products), it is effective with less drying. Use on affected areas rather than the whole face to limit barrier disruption.

Benzoyl peroxide (2.5–5%) – directly kills C. acnes bacteria through oxidative mechanisms; no antibiotic resistance is possible. At 2.5%, essentially equivalent efficacy to 10% with significantly less irritation. For menopausal skin, use as a spot treatment on individual lesions rather than as an all-over wash-off treatment. Has bleaching effect on towels and bedding – use white for pillowcases.

Topical retinoids (adapalene 0.1–0.3%, tretinoin 0.025–0.05%) – the most evidence-supported topical treatment for acne overall. They normalize follicular keratinisation (cell shedding within pores), reduce comedone formation, and have direct anti-inflammatory properties. For menopausal skin, the introduction protocol is critical: begin with the lowest available strength 2–3 times weekly, applied to dry skin 20–30 minutes after cleansing, over a ceramide-heavy moisturizer. Gradually increase frequency over 6–8 weeks as tolerance develops. The retinisation period (initial purging, peeling, and redness) is longer and more intense on menopausal skin – this is not an indication to stop but to slow down.

Topical clascoterone (Winlevi, 1%) – the newest topical anti-androgen, specifically approved for hormonal acne. It blocks androgen receptors within the skin itself, without systemic anti-androgenic effects. Appropriate for women who cannot use oral anti-androgens; provides the topical equivalent of spironolactone’s mechanism. Not yet available in all markets.

Step 3: Oral Antibiotics – Bridge Therapy

For moderate to severe inflammatory acne that has not responded to topical treatment alone, oral antibiotics provide a temporary bridge while longer-acting hormonal treatments establish effect.

Doxycycline (40–100 mg daily) or lymecycline (408 mg daily) – tetracycline-class antibiotics with anti-bacterial and anti-inflammatory properties. The current clinical standard is to limit oral antibiotic courses to a maximum of 3 months and always to combine with a topical retinoid or benzoyl peroxide to reduce resistance risk. Oral antibiotics should never be used as monotherapy or for maintenance – resistance patterns in C. acnes are an increasing clinical concern.

Erythromycin and azithromycin – alternative options where tetracyclines are not tolerated.

Antibiotics address the bacterial and inflammatory components of acne but do not address the underlying hormonal driver. They are therefore a bridge – providing faster initial response while hormonal treatments take effect – rather than a long-term solution.

Step 4: Systemic Hormonal Treatment – The Most Mechanistically Targeted Approach

This is where treatment for perimenopausal and menopausal acne diverges most significantly from the management of acne in other age groups. The hormonal driver is specific and identifiable – and treating the hormonal cause is more effective and more durable than indefinite topical or antibiotic management.

Spironolactone – The Most Evidence-Supported Option

Spironolactone is a potassium-sparing diuretic with potent anti-androgenic properties. It works by blocking androgen receptors in sebaceous glands, reducing sebum production, and reducing the androgen-driven follicular hyperkeratinisation underlying hormonal acne. It is not effective in men (due to the feminizing effects of androgen blockade at the doses required) and is prescribed exclusively for female patients.

Spironolactone is an effective acne treatment with clinical trial data to support its use as a first-line treatment for women with acne. From clinical experience, spironolactone helps control acne in approximately 70% of women; however, several studies have shown improvement rates between 71–93%. Spironolactone works by blocking the effects of androgens and progesterone on the skin and is particularly useful in those whose acne is caused by sensitivity to progesterone.

Dosing protocol: Start at 25–50 mg daily for the first 4–6 weeks; increase to 75–100 mg daily if well-tolerated and response is insufficient; in resistant cases, doses up to 200 mg daily are used with clinical monitoring. The dose response for acne peaks at 100–150 mg in most patients.

Time to response: 3 months minimum for meaningful improvement; full benefit is typically assessed at 6 months. Patience and clear expectation-setting are essential – women who stop at 6–8 weeks have not given the treatment a fair trial.

Side effects: Menstrual irregularity (common at higher doses in pre-menopausal women; typically not relevant in postmenopausal women), breast tenderness, urinary frequency (diuretic effect), and rarely potassium elevation (clinical monitoring of electrolytes is recommended at initiation and 3 months). The potassium elevation risk is practically low in otherwise healthy women who are not on potassium-sparing medications.

Contraindications: Pregnancy (requires reliable contraception in pre-menopausal women; not relevant in postmenopause), significant renal impairment, potassium-elevating medications.

Topical Finasteride – Emerging Evidence

Topical finasteride (0.25–1% cream or gel) inhibits 5-alpha-reductase at the skin level – reducing the conversion of testosterone to DHT within the sebaceous gland – without the systemic anti-androgenic effects of oral finasteride. Emerging clinical data supports its use for both acne and female pattern hair loss; it is not yet widely available but represents an important developing option.

Combined Oral Contraceptives (COC) in Perimenopause

COC formulations with anti-androgenic progestins (cyproterone acetate, chlormadinone, drospirenone) reduce ovarian androgen production and raise sex hormone-binding globulin (SHBG), reducing free testosterone availability. They are a recognized treatment for hormonal acne and additionally provide contraception – relevant in perimenopause, as ovulation remains possible until the final menstrual period.

Drospirenone-containing combined pills (Yasmin, Yaz) are specifically licensed for acne treatment. However, their use becomes more complex in the perimenopausal period as cardiovascular risk increases with age, and they are generally not recommended beyond age 50 or in women with migraine with aura, hypertension, or significant cardiovascular risk factors. Clinical judgement and individual risk assessment are essential.

Hormone Replacement Therapy and Acne

The relationship between HRT and acne is nuanced and formulation-dependent:

The most effective treatment for adult acne is usually some form of hormonal therapy. For menopausal women, this means hormone replacement therapy. Some women who start HRT report that their complexion has cleared up, while others find that it has made their acne troubles worse.

The effect of HRT on acne depends primarily on the progestogen component. Synthetic progestins – particularly levonorgestrel, norethisterone, and medroxyprogesterone acetate – have androgenic activity and can worsen acne in susceptible women. Oral micronized progesterone (OMP) and dydrogesterone – the most physiological progestogen options – have minimal androgenic activity and are generally acne-neutral or modestly beneficial. Transdermal rather than oral estrogen produces more stable estrogen levels and is less likely to trigger the estrogen-surge sebum stimulation discussed earlier.

For women with significant menopausal symptoms alongside hormonal acne, discussing HRT formulation choice with a menopause specialist – specifically selecting an anti-androgenic or androgenically neutral progestogen – is both appropriate and clinically well-supported.

Step 5: Isotretinoin – For Severe, Scarring, Or Treatment-Resistant Acne

Isotretinoin (Roaccutane; Accutane) is a systemic vitamin A derivative that produces the most profound and durable acne remission of any available treatment. It works through four simultaneous mechanisms: dramatically reducing sebaceous gland size and sebum production, normalizing follicular cell shedding, reducing C. acnes colonization, and producing sustained anti-inflammatory effects.

Isotretinoin, as a vitamin A derivative, shrinks sebaceous glands to significantly reduce oil production. Less oil means fewer clogged pores and a less hospitable environment for acne-causing bacteria. Clinical studies show that up to 85% of patients achieve long-term remission after completing a single 4–6-month course. Its multi-faceted approach often leads to dramatic, long-term improvements.

For perimenopausal and menopausal women, isotretinoin is indicated for severe acne (nodulo-cystic), significant scarring risk, or acne that has failed to respond to adequate trials of topical treatment, antibiotics, and spironolactone.

Dosing in menopausal women: Standard protocols use 0.5–1 mg/kg daily for 4–6 months. Emerging evidence supports a micro-dosing protocol (10–20 mg daily or alternate-day) in older adults, which produces equivalent remission with significantly fewer side effects – particularly relevant for the xerosis (extreme dryness) that full-dose isotretinoin produces in menopausal skin already prone to dryness.

Key side effects to manage:

• Extreme dryness – lips, skin, nasal mucosa, eyes. Require intensive moisturization, lip balm, preservative-free lubricating eye drops, and humidification. More severe in menopausal skin – proactive management from day 1 is essential.
• Elevated lipids – triglyceride and cholesterol monitoring is required at baseline, 6 weeks, and end of treatment. Relevant in menopausal women with metabolic risk factors.
• Mood changes – monitor for depressive symptoms; existing mental health should be stable before initiating.
• Teratogenicity – not clinically relevant in confirmed menopausal women (12 months amenorrhea), but remains a clinical check in perimenopausal women.

Isotretinoin is a prescription-only treatment requiring specialist (dermatologist) supervision and, in many countries, a formal pregnancy prevention program at any age during the reproductive and perimenopausal years.

Part 4: In-Clinic Procedures for Acne Management

For women with active lesions, post-acne scarring, or post-inflammatory hyperpigmentation (PIH), clinical procedures provide targeted benefit that topical products cannot deliver:

Chemical peels – glycolic acid (20–50%), salicylic acid (20–30%), or mandelic acid (30%) peels provide accelerated exfoliation, comedolysis, and anti-inflammatory benefit. Glycolic acid peels simultaneously stimulate collagen production – directly addressing the skin ageing dimension of menopausal skin alongside the acne. A series of 4–6 peels at 2–4 week intervals is typical.

Microneedling – collagen-induction therapy that creates controlled micro-injuries stimulating wound healing and collagen remodeling. Particularly valuable for post-acne scarring and textural irregularity, which are more significant concerns in menopausal skin (where collagen loss compounds the scarring impact of acne). May be combined with topical delivery of vitamin C, niacinamide, or hyaluronic acid through the microchannels created.

LED light therapy – blue light (415nm) directly inhibits C. acnes activity through porphyrin photosensitization; red light (630nm) has anti-inflammatory and wound-healing properties. Combined blue-red LED therapy produces moderate but consistent benefit for inflammatory acne. Available both in-clinic and as home devices; most evidence supports regular use (3–5 sessions weekly) for consistent benefit.

Laser treatments – intense pulsed light (IPL) reduces PIH and vascular inflammation; fractional ablative lasers address scarring. These are adjuncts to – not substitutes for – the medical treatment of active acne.

Part 5: Nutrition, Lifestyle, and the Diet-Acne Relationship

The AAD 2024 guidelines note that “available evidence was insufficient to develop recommendations for dietary changes” – and this honest acknowledgement of the evidence base is important context. However, several dietary patterns have biological plausibility and modest clinical support:

Low glycemic diet – the strongest evidence connects high glycemic index diets to acne through IGF-1 (insulin-like growth factor 1) signaling, which directly stimulates sebaceous gland activity and androgen production. A diet based on whole grains, legumes, vegetables, and lean protein, avoiding refined carbohydrates and sugar, reduces this IGF-1 drive on sebaceous activity. In perimenopausal women, this dietary pattern simultaneously addresses insulin resistance – a concurrent priority.

Dairy moderation – the association between milk consumption (particularly skim milk) and acne is observed in epidemiological studies and proposed to operate through dairy-derived IGF-1 and whey protein-driven insulin and IGF-1 spikes. The evidence is associative rather than interventional, but moderation is a reasonable consideration in women with persistent acne.

Omega-3 fatty acids – anti-inflammatory; directly relevant to the inflammatory component of acne. 2–3g EPA+DHA daily.

Zinc – a co-factor for 5-alpha-reductase regulation and an anti-inflammatory mineral with modest clinical evidence for acne. Zinc gluconate or picolinate at 30 mg daily is the dose used in acne trials. Avoid at doses above 40 mg daily (copper absorption interference).

Probiotics – the gut-skin axis is an active research frontier. Dysbiotic gut microbiomes produce systemic inflammatory signals that worsen skin inflammation; Lactobacillus and Bifidobacterium supplementation has demonstrated modest but positive effects on acne inflammatory scores in small RCTs. Dietary fermented foods (yogurt, kefir, kimchi, sauerkraut) support gut Lactobacillus populations.

Stress management – given cortisol’s direct stimulatory effect on sebaceous glands, any evidence-based stress reduction practice (mindfulness, exercise, adequate sleep) is a direct anti-acne intervention. This is not a soft lifestyle recommendation – it is a mechanistically grounded clinical one.

Part 6: The Practical Treatment Protocol by Severity

Mild hormonal acne (few inflammatory papules, predominantly comedonal):

1. Gentle cleanser + ceramide moisturizer + SPF 30+ daily
2. Azelaic acid 10% twice daily (or once daily initially)
3. Niacinamide 4–5% serum
4. Consider topical retinoid introduced gradually 2–3x weekly
5. Dietary and lifestyle modifications (low GI, omega-3, stress)

Moderate hormonal acne (multiple inflammatory papules/pustules, some deeper lesions):

1. All of Step 1 foundation care
2. Azelaic acid 15–20% (prescription) + topical retinoid
3. Spironolactone 50–100 mg daily – initiate with dermatology or GP
4. If rapid bridging needed: 3-month course of doxycycline alongside while spironolactone takes effect
5. Dietary modifications + stress management

Severe hormonal acne (nodulo-cystic, significant scarring, failed prior treatments):

1. Foundation care
2. Spironolactone at therapeutic dose (100–150 mg daily)
3. If inadequate response at 6 months: referral for isotretinoin assessment (standard or micro-dosing protocol)
4. In-clinic procedures for scarring: microneedling, chemical peels, fractional laser
5. Discuss MHT formulation with menopause specialist – switch to androgenically neutral progestogen if on HRT

The Conclusion

Hormonal acne during perimenopause and menopause is one of the most clinically mismanaged skin conditions in this demographic. Women are dismissed with teenage acne protocols, given antibiotics without hormonal management, or simply told that nothing can be done. None of these responses reflects current evidence.

The treatment landscape – from topical azelaic acid and retinoids, through spironolactone as the gold-standard oral anti-androgen, to micro-dose isotretinoin for the most severe cases, with HRT formulation optimization for women managing both acne and menopausal symptoms – is comprehensive, evidence-graded, and significantly more effective than most women are told.

The skin can clear. The scarring can be treated. The confidence that breakouts at this life stage have taken can be recovered. But it requires a treatment approach that understands the mechanism – and a clinician willing to address it directly.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Sources

1. Tan J et al. How to Best Support Women With Menopausal Acne. Dermatology Times. April 2025;46(4). (PMC12860752 context; citing 12–22% prevalence)
2. American Academy of Dermatology (AAD). Updated Guidelines for the Management of Acne. aad.org. January 2024. (Citing updated 2024 AAD acne guidelines)
3. Smith CA et al. Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists. Dermatology and Therapy. 2025;15(1):45–59. PMC11785877. doi:10.1007/s13555-024-01324-8
4. Tommasino N et al. Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review. Clinical, Cosmetic and Investigational Dermatology. 2025;18:3331–3337. doi:10.2147/CCID.S574341
5. Burns LJ et al. Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review. Journal of the American Academy of Dermatology. 2025. doi:10.1016/S0190-9622(25)00722-4
6. Skindoc UK. Spironolactone – Everything You Need to Know. skindoc.uk. 2025. (Citing 71–93% improvement rate clinical studies)
7. Hellowisp. What Is Spironolactone? hellowisp.com. January 2025.
8. Midland Skin. Spironolactone for Hormonal Acne. midlandskin.co.uk. 2025.
9. Oana Health. Spironolactone vs. Isotretinoin: Hormonal Acne Explained. oanahealth.com. 2025. (Citing 85% long-term remission with isotretinoin data)
10. Clear Health. Menopause and Estrogen-Related Acne: Causes, Treatments. helloclearhealth.com. 2025.
11. Dr Aliabadi. Perimenopause and Acne. draliabadi.com. June 2025.
12. Healthline. Does Menopause Cause Acne? healthline.com. Updated 2024.
13. Aol/Byrdie. Menopausal Acne Happens, And You Have Options. 2025. (Citing Dr. Heather Rodney, dermatologist)
14. ClinicalTrials.gov NCT04582383. Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne.clinicaltrials.gov.
15. Reynolds RV et al. Guidelines of Care for the Management of Acne Vulgaris. Journal of the American Academy of Dermatology. 2024;90(5):1006–1023. doi:10.1016/j.jaad.2023.12.048 (AAD 2024 Full Guidelines)
16. Arowojolu AO et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews. 2012. doi:10.1002/14651858.CD004425.pub6
17. Zaenglein AL. Acne Vulgaris. New England Journal of Medicine. 2018;379:1343–1352. doi:10.1056/NEJMcp1702493
18. Kaymak Y et al. Dietary glycemic index and acne. Journal of the American Academy of Dermatology. 2007;57:247–254.
19. Zouboulis CC, Blume-Peytavi U. Effect of estrogens on skin ageing and the potential role of SERMs. Clinical Interventions in Aging. 2008;3(2):283–297. PMC2685269.
20. Kim EJ et al. Skincare ingredients recommended by cosmetic dermatologists: A Delphi consensus study. Journal of the American Academy of Dermatology. 2025. doi:10.1016/j.jaad.2025.03.062